Advanced steatosis kept hepatocellular carcinoma risk elevated after hepatitis C cure
In patients who cleared hepatitis C but remained burdened by metabolic dysfunction-associated steatotic liver disease, the liver did not fully reset to a low-risk state. In this Gut cohort, the depth of residual fat accumulation inside the liver mattered more than the broader cardiometabolic profile when investigators tracked later hepatocellular carcinoma events.
Seven hundred patients entered biannual cancer surveillance after hepatitis C cure, giving the analysis a long enough clinical runway to separate background metabolic noise from signals that appeared genuinely linked to cancer risk. Steatosis was graded by vibration-controlled transient elastography using controlled attenuation parameter cut-offs that mapped to S1, S2, and S3. The study also captured cardiometabolic risk factors at the time of viral cure, then compared cumulative HCC incidence across steatosis grades and across overall cardiometabolic burden.
The separation was not subtle. Cumulative HCC incidence differed significantly across steatosis grades, with the clearest divergence emerging in those with advanced fat accumulation. A one-sentence clinical truth sits at the center of the dataset: a fatty liver after cure is not a neutral liver.
Steatosis grade outperformed the total cardiometabolic count
Advanced hepatic steatosis remained independently associated with HCC risk in multivariable analysis adjusted for age, sex, liver stiffness, and alpha-fetoprotein. The strongest signal appeared in the S3 group, which carried an adjusted hazard ratio of 2.15 versus S1, with a 95% confidence interval of 1.25 to 3.69 and a p value of 0.005. Fine-Gray sensitivity analyses confirmed the same direction of effect.
By contrast, the overall cardiometabolic burden did not separate risk in a statistically significant way. Cumulative HCC incidence did not differ across cardiometabolic burden strata, with a p value of 0.62. In practical terms, the number of metabolic diagnoses on paper was less informative than the degree of steatosis already present in the liver tissue surrogate measured at the bedside.
That pattern argues for a pathobiology centered on the liver itself rather than on a simple tally of metabolic comorbidities. Persistent intrahepatic fat can promote lipotoxic stress, oxidative injury, mitochondrial dysfunction, and inflammatory signaling, all of which can support fibrogenesis and malignant transformation even after hepatitis C eradication removes the original viral driver. Cure removes one carcinogenic engine, but residual steatotic injury can keep the microenvironment primed for neoplasia.
Glycaemic dysfunction carried a separate cancer signal
Among individual cardiometabolic risk factors, pre-diabetes or type 2 diabetes stood out. Glycaemic abnormality was significantly associated with HCC risk, with an adjusted hazard ratio of 2.33, a 95% confidence interval of 1.38 to 3.94, and a p value of 0.002. No comparable association emerged for the aggregate cardiometabolic burden itself.
This distinction is clinically important because diabetes is not merely a marker of metabolic illness; it can directly amplify oncogenic pressure through hyperinsulinaemia, insulin resistance, and downstream growth signaling. Hepatic fat plus disordered glucose handling forms a biologically plausible tandem. The former reflects structural injury within the liver, while the latter supplies a systemic pro-growth environment that may accelerate clonal selection in premalignant tissue.
The data therefore split metabolic risk into two different questions. One asks how much steatosis remains embedded in the liver. The other asks whether glycaemic dysregulation is still pushing hepatocellular proliferation from outside the liver. In this cohort, both questions mattered, but in different ways and with different strengths of association.
Why the aggregate cardiometabolic score was less informative
A broad cardiometabolic burden score can flatten clinically distinct pathways into a single composite. Hypertension, dyslipidaemia, obesity-related traits, and glucose abnormalities do not necessarily exert the same pressure on hepatocarcinogenesis, especially once hepatitis C has been cured and the viral contribution has been removed. A composite count may therefore dilute the effects of the variables most tightly linked to liver cancer biology.
Steatosis grading, by contrast, directly interrogates the organ at risk. Controlled attenuation parameter thresholds offered a noninvasive way to stratify liver fat burden, and the stepwise association with HCC risk suggests a dose-response relationship rather than a binary threshold effect. Patients with S3 disease carried the highest risk, fitting the expectation that heavier fat loading creates a more hostile hepatic milieu over time.
The study design also strengthens the message. All patients underwent biannual HCC surveillance after HCV cure, limiting the chance that cancer would simply be missed in one subgroup more than another. Multivariable Cox modeling with selection based on Akaike Information Criterion, along with Fine-Gray sensitivity analyses, gave the findings statistical robustness without changing the core result.
Post-cure surveillance may need to track the liver, not just the metabolic checklist
For clinicians caring for patients after hepatitis C cure, the message is not that every metabolic abnormality carries identical weight. It is that advanced steatosis and glycaemic dysfunction deserve special attention when deciding who remains vulnerable to HCC despite viral eradication. A patient with a low-risk looking metabolic checklist may still carry substantial cancer risk if steatosis remains severe.
This has practical implications for follow-up discussions in hepatology clinics. Liver fat burden, as measured noninvasively, may help identify which patients need sustained surveillance intensity even after cure. Diabetes and pre-diabetes also deserve close management, not only for vascular and renal outcomes but because they appear to track with liver cancer risk in this post-HCV setting.
No single marker fully captures the residual carcinogenic environment after hepatitis C is gone. The liver remembers the metabolic injury that remains. In this cohort, the memory was written more clearly in steatosis grade and glycaemic abnormality than in the combined burden score.
Residual uncertainty after viral cure
The study does not support treating all forms of cardiometabolic burden as interchangeable predictors of hepatocellular carcinoma. It also leaves open whether aggressive metabolic intervention after HCV cure can reduce later cancer incidence, or whether the observed associations mainly identify patients already on a high-risk trajectory. Those questions will require prospective interventional work rather than surveillance data alone.
For now, the strongest evidence points to a narrow clinical lesson: after HCV cure, severe hepatic steatosis and pre-diabetes or type 2 diabetes mark the patients most likely to remain at elevated HCC risk.